InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease. Under the terms of the option ...

Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

EYEspa has released a new guide on the connection between omega-3 fatty acids and eye health, exploring how maintaining ...

However, the effect of cataract surgery on other measures of dry eye is unclear, with inconsistent outcomes across studies. Researchers conducted a systematic review of 20 observational studies ...

These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...